This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Janet L. Stanford, PhD; Noel S. Weiss, MD, DrPH; Lynda F. Voigt, PhD; Janet R. Daling, PhD; Laurel A. Habel, MPH; Mary Anne Rossing, PhD

JAMA. 1995;274(2):137-142.

Abstract
Objective.
—To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT).

Design.
—A population-based case-control study.

Setting.
—The general female population of King County in western Washington State.

Participants.
—Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1,1988, and June 30, 1990, who were ascertained through the Seattle—Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer.

Main Outcome Measure.
—Breast cancer risk in relation to use of menopausal hormones.

Results.
—Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO]=0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO=0.4; 95% CI, 0.2 to 1.0).

Conclusions.
—On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users.

(JAMA. 1995;274:137-142)

Author Affiliations
From the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Drs Stanford, Weiss, Voigt, Daling, and Rossing, and Ms Habel), and Department of Epidemiology, School of Public Health and Community Medicine, University of Washington (Drs Stanford, Weiss, Daling, and Rossing, and Ms Habel), Seattle, Wash.

Footnotes
Reprint requests to Fred Hutchinson Cancer Research Center, 1124 Columbia St, MP-474, Seattle, WA 98104 (Dr Stanford).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk
Shantakumar et al.
Am J Epidemiol 2007;165:1187-1198.
ABSTRACT | FULL TEXT  

Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Zhang et al.
Am J Epidemiol 2007;165:524-529.
ABSTRACT | FULL TEXT  

Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration
Warren
Mayo Clin Proc. 2007;82:219-226.
ABSTRACT | FULL TEXT  

Bayesian Network to Predict Breast Cancer Risk of Mammographic Microcalcifications and Reduce Number of Benign Biopsy Results: Initial Experience
Burnside et al.
Radiology 2006;240:666-673.
ABSTRACT | FULL TEXT  

Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004
McPherson and Mant
J. Epidemiol. Community Health 2005;59:1078-1079.
FULL TEXT  

Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Greiser et al.
Hum Reprod Update 2005;11:561-573.
ABSTRACT | FULL TEXT  

Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Colditz
Clin. Cancer Res. 2005;11:909s-917s.
ABSTRACT | FULL TEXT  

Ductal Carcinoma In Situ, Complexities and Challenges
Leonard and Swain
JNCI J Natl Cancer Inst 2004;96:906-920.
ABSTRACT | FULL TEXT  

Hormonal Factors and the Risk of Breast Cancer According to Estrogen- and Progesterone-Receptor Subgroup
Cotterchio et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1053-1060.
ABSTRACT | FULL TEXT  

Characteristics of Telephone Survey Respondents According to Willingness to Participate
Voigt et al.
Am J Epidemiol 2003;157:66-73.
ABSTRACT | FULL TEXT  

Postmenopausal Estrogen and Progestin Use in Relation to Breast Cancer Risk
Newcomb et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:593-600.
ABSTRACT | FULL TEXT  

Risk of Subsequent Breast Cancer in Relation to Characteristics of Screening Mammograms from Women Less Than 50 Years of Age
Thomas et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:565-571.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy in Relation to Breast Cancer
Chen et al.
JAMA 2002;287:734-741.
ABSTRACT | FULL TEXT  

Breast Carcinoma In Situ: Risk Factors and Screening Patterns
Claus et al.
JNCI J Natl Cancer Inst 2001;93:1811-1817.
ABSTRACT | FULL TEXT  

Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy
Alexandersen et al.
J. Clin. Endocrinol. Metab. 2001;86:755-760.
ABSTRACT | FULL TEXT  

Breast Cancer Risk and "Delayed" Primary Epstein-Barr Virus Infection
Yasui et al.
Cancer Epidemiol. Biomarkers Prev. 2001;10:9-16.
ABSTRACT | FULL TEXT  

Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy
Santen et al.
J. Clin. Endocrinol. Metab. 2001;86:16-23.
FULL TEXT  

Hormone replacement therapy: changes in frequency and type of prescription by Dutch GPs during the last decade of the millennium
Donker et al.
Fam Pract 2000;17:508-513.
ABSTRACT | FULL TEXT  

Breast cancer hypothesis: a single cause for the majority of cases
Wiseman
J. Epidemiol. Community Health 2000;54:851-858.
ABSTRACT | FULL TEXT  

Risk Factors for Carcinoma in Situ of the Breast
Trentham-Dietz et al.
Cancer Epidemiol. Biomarkers Prev. 2000;9:697-703.
ABSTRACT | FULL TEXT  

Discussion of Hormone Replacement Therapy Between Physicians and Their Patients
Schneider et al.
American Journal of Medical Quality 2000;15:143-147.
ABSTRACT  

Anthropometric variables in relation to risk of breast cancer in middle-aged women
Li et al.
Int J Epidemiol 2000;29:208-213.
ABSTRACT | FULL TEXT  

Risk of breast cancer associated with hormone replacement therapy
Dopp and Kolesar
J Oncol Pharm Pract 1999;5:109-116.
ABSTRACT  

Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology: Results of the Iowa Women's Health Study
Gapstur et al.
JAMA 1999;281:2091-2097.
ABSTRACT | FULL TEXT  

Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
Hosking et al.
NEJM 1998;338:485-492.
ABSTRACT | FULL TEXT  

Biphasic Regulation of Breast Cancer Cell Growth by Progesterone: Role of the Cyclin-Dependent Kinase Inhibitors, p21 and p27Kip1
Groshong et al.
Mol. Endocrinol. 1997;11:1593-1607.
ABSTRACT | FULL TEXT  

Duration of Estrogen Replacement Therapy in Relation to the Risk of Incident Myocardial Infarction in Postmenopausal Women
Heckbert et al.
Arch Intern Med 1997;157:1330-1336.
ABSTRACT  

The Critical Role of Alcohol Consumption in Determining the Risk of Breast Cancer with Postmenopausal Estrogen Administration
Zumoff
J. Clin. Endocrinol. Metab. 1997;82:1656-1658.
FULL TEXT  

Characteristics of Women With and Without Breast Augmentation
Cook et al.
JAMA 1997;277:1612-1617.
ABSTRACT  

Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women
Col et al.
JAMA 1997;277:1140-1147.
ABSTRACT  

Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2
Burke et al.
JAMA 1997;277:997-1003.
ABSTRACT  

Estrogen Replacement
Sullivan
Circulation 1996;94:2699-2702.
FULL TEXT  

May depend on whether the menopause is regarded as physiological or pathological
Hinshaw
BMJ 1996;313:686a-686.
FULL TEXT  

Authors gave distorted view through selective citation
Ross et al.
BMJ 1996;313:686b-687.
FULL TEXT  

General Internal Medicine
Petersen and Daley
JAMA 1996;275:1811-1812.
ABSTRACT  

Hormone Replacement Therapy and Breast Cancer Risk
Gambrell
Arch Fam Med 1996;5:341-348.
ABSTRACT  

Hormone Replacement Therapy and Breast Cancer
Stanford and Weiss
Arch Fam Med 1996;5:349-350.
ABSTRACT  

Hormone Replacement Therapy and Breast Cancer Risk
Campagnoli et al.
JAMA 1996;275:1159-1159.
ABSTRACT  

Hormone Replacement Therapy and Breast Cancer Risk
Harris et al.
JAMA 1996;275:1158-1159.
ABSTRACT  

Women and coronary heart disease
DTB 1996;34:28-30.
ABSTRACT | FULL TEXT  

Postmenopausal Estrogens and Breast Cancer
Colditz
Reproductive Sciences 1996;3:50-56.
 

MORE DATA, MORE CONFUSION ON HORMONES AND BREAST CANCER
JWatch General 1995;1995:2-2.
FULL TEXT  

Hormone Replacement and Breast Cancer: A Remaining Controversy?
Adami and Persson
JAMA 1995;274:178-179.
ABSTRACT